Enfusion

Enfusion Receivables

Delisted

The Accounts Receivable of Enfusion (ENFN) as of Nov 7, 2026 is 31.99 M USD. In the previous year, Accounts Receivable was 28.07 M USD — a change of 13.96% (higher).

Receivables

31.99 MUSD

YoY

13.96%

Last updated:

Accounts Receivable of Enfusion is 2024 31.99 M USD. Accounts Receivable of Enfusion was 2023 28.07 M USD. It decreases by 13.96% higher compared to the previous year.

The Enfusion Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2019
9.00 M USD
Jan 1, 2020
12.20 M USD
Jan 1, 2021
18.20 M USD
Jan 1, 2022
25.90 M USD
Jan 1, 2023
28.07 M USD
Jan 1, 2024
31.99 M USD
The Enfusion Receivables history
YEARReceivablesYoY
31.99 MUSD+13.96%
28.07 MUSD+8.37%
25.90 MUSD+42.31%
18.20 MUSD+49.18%
12.20 MUSD+35.56%
9.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enfusion Stock analysis

What does Enfusion do? Enfusion Inc. generates revenue through cloud-native multi-tenant software solutions tailored for alternative and institutional investment managers. Its core products include the Portfolio Management System (PMS), Order and Execution Management System (OEMS), Accounting/General Ledger System, and Enfusion Analytics System, which collectively enable real-time investment decision-making. The company serves investment managers who require integrated systems for the full investment lifecycle, with PMS constructing and rebalancing portfolios while generating a real-time investment book of record, and OEMS facilitating electronic trade order communication for portfolio managers, traders, compliance teams, and analysts. The company's solution integrates technology-powered managed services to drive insights and control over investment operations. Enfusion's end-to-end functionality supports the entire investment process, from portfolio construction to trade execution, with PMS and OEMS operating in tandem to provide a seamless workflow. Investment managers across alternative and institutional segments purchase these integrated systems to enhance operational efficiency and decision-making capabilities. Enfusion's software is designed to serve the full investment lifecycle, with its systems integrated to provide a unified platform for portfolio management, order execution, accounting, and analytics. The company's revenue model is based on delivering these comprehensive solutions to investment managers who rely on real-time data and integrated workflows to manage their operations effectively. Enfusion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enfusion stock

Accounts Receivable of Enfusion is 31.99 M USD in 2024.

Accounts Receivable of Enfusion changed from 28.07 M USD to 31.99 M USD, representing a 13.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Enfusion since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Enfusion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Enfusion

All Key Metrics — Enfusion